Rob Boddice (ed.), Pain and Emotion in Modern History
In: Social history of medicine, Band 28, Heft 2, S. 393-395
ISSN: 1477-4666
12 Ergebnisse
Sortierung:
In: Social history of medicine, Band 28, Heft 2, S. 393-395
ISSN: 1477-4666
In: Peace research abstracts journal, Band 44, Heft 4, S. 83
ISSN: 0031-3599
In: Social identities: journal for the study of race, nation and culture, Band 2, Heft 1
ISSN: 1350-4630
In: Yearbook of European law, Band 9, Heft 1, S. 175-196
ISSN: 2045-0044
In: African Safety Promotion: A Journal of Injury and Violence Prevention, Band 7, Heft 2
ISSN: 1728-774X
In: The British journal of social work, Band 19, Heft 6, S. 461-477
ISSN: 1468-263X
In: African Safety Promotion: A Journal of Injury and Violence Prevention, Band 7, Heft 2
ISSN: 1728-774X
Hepatitis C virus (HCV) among injecting drug users (IDUs) is one of the European Union's (EU) major public health problems. This review examines the current state of knowledge regarding HCV among IDUs in EU countries. Studies published between January 1990 and December 2000, were identified through a computerized search (MEDLINE and EMBASE). Ninety-eight studies have reported prevalence for HCV among groups of IDUs in all EU countries except Luxembourg. The prevalence of anti-HCV ranged from 30 to 98%. Incidence rates ranged from 6.2 to 39.3 per 100 person years. This review provides a comprehensive examination of HCV infection among IDUs in the countries of the EU, and quite clearly demonstrates that the quality and epidemiological relevance of the studies published varies widely. Thus, the reported data may not reflect accurately the current or recent past prevalence of HCV among IDUs in the EU. A strategic approach to the surveillance of HCV among IDUs in the EU, utilizing robust and consistent methods, is required urgently.
BASE
BACKGROUND AND AIMS: To reduce hepatitis C virus (HCV) transmission among people who inject drugs (PWID), Scottish Government-funded national strategies, launched in 2008, promoted scaling-up opioid substitution therapy (OST) and needle and syringe provision (NSP), with some increases in HCV treatment. We test whether observed decreases in HCV incidence post-2008 can be attributed to this intervention scale-up. DESIGN: A dynamic HCV transmission model amongst PWID incorporating intervention scale-up and observed decreases in behavioural risk, calibrated to Scottish HCV prevalence and incidence data for 2008/09. SETTING: Scotland, UK PARTICIPANTS: PWID MEASUREMENTS: Model projections from 2008–2015 were compared with data to test whether they were consistent with observed decreases in HCV incidence amongst PWID while incorporating the observed intervention scale-up, and to determine the impact of scaling-up interventions on incidence. FINDINGS: Without fitting to epidemiological data post-2008/09, the model incorporating observed intervention scale-up agreed with observed decreases in HCV incidence amongst PWID between 2008–2015, suggesting HCV incidence decreased by 61.3% (95% credibility interval 45.1–75.3%) from 14.2/100pyrs (9.0–20.7) to 5.5/100pyrs (2.9–9.2). On average, each model fit lay within 84% (10.1/12) of the confidence bounds for the 12 incidence data points which the model was compared against. We estimate that scale-up of interventions (OST+NSP+HCV treatment) and decreases in high-risk behaviour from 2008–2015 resulted in a 33.9% (23.8–44.6%) decrease in incidence, with the remainder (27.4% (17.6–37.0%)) explained by historical changes in OST+NSP coverage and risk pre-2008. Projections suggest scaling-up of all interventions post-2008 averted 1,492 (657–2,646) infections over 7-years, with 1,016 (308–1,996), 404 (150–836) and 72 (27–137) due to scale-up of OST+NSP, decreases in high-risk behaviour, and HCV treatment, respectively. CONCLUSIONS: Most of the decline in hepatitis C virus (HCV) ...
BASE
In: Fraser , H , Mukandavire , C , Martin , N K , Goldberg , D , Palmateer , N , Munro , A , Taylor , A , Hickman , M , Hutchinson , S & Vickerman , P 2018 , ' Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland ' , Addiction , vol. 113 , no. 11 , pp. 2118-2131 . https://doi.org/10.1111/add.14267
Background and Aims: To reduce hepatitis C virus (HCV) transmission among people who inject drugs (PWID), Scottish Government-funded national strategies, launched in 2008, promoted scaling-up opioid substitution therapy (OST) and needle and syringe provision (NSP), with some increases in HCV treatment. We test whether observed decreases in HCV incidence post-2008 can be attributed to this intervention scale-up. Design: A dynamic HCV transmission model among PWID incorporating intervention scale-up and observed decreases in behavioural risk, calibrated to Scottish HCV prevalence and incidence data for 2008/09. Setting: Scotland, UK. Participants: PWID. Measurements: Model projections from 2008 to 2015 were compared with data to test whether they were consistent with observed decreases in HCV incidence among PWID while incorporating the observed intervention scale-up, and to determine the impact of scaling-up interventions on incidence. Findings: Without fitting to epidemiological data post-2008/09, the model incorporating observed intervention scale-up agreed with observed decreases in HCV incidence among PWID between 2008 and 2015, suggesting that HCV incidence decreased by 61.3% [95% credibility interval (CrI) = 45.1–75.3%] from 14.2/100 person-years (py) (9.0–20.7) to 5.5/100 py (2.9–9.2). On average, each model fit lay within 84% (10.1/12) of the confidence bounds for the 12 incidence data points against which the model was compared. We estimate that scale-up of interventions (OST + NSP + HCV treatment) and decreases in high-risk behaviour from 2008 to 2015 resulted in a 33.9% (23.8–44.6%) decrease in incidence, with the remainder [27.4% (17.6–37.0%)] explained by historical changes in OST + NSP coverage and risk pre-2008. Projections suggest that scaling-up of all interventions post-2008 averted 1492 (657–2646) infections over 7 years, with 1016 (308–1996), 404 (150–836) and 72 (27–137) due to scale-up of OST + NSP, decreases in high-risk behaviour and HCV treatment, respectively. Conclusions: Most of the decline in hepatitis C virus (HCV) incidence in Scotland between 2008 and 2015 appears to be attributable to intervention scale-up (opioid substitution therapy and needle and syringe provision) due to government strategies on HCV and drugs.
BASE
In: Twin research, Band 3, Heft 4, S. 316-322
ISSN: 2053-6003
Background: People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment options are improving and may enhance prevention; however access for PWID may be poor. The availability in the literature of information on seven main topic areas (incidence, chronicity, genotypes, HIV co-infection, diagnosis and treatment uptake, and burden of disease) to guide HCV treatment and prevention scale-up for PWID in the 27 countries of the European Union is systematically reviewed. Methods and Findings: We searched MEDLINE, EMBASE and Cochrane Library for publications between 1 January 2000 and 31 December 2012, with a search strategy of general keywords regarding viral hepatitis, substance abuse and geographic scope, as well as topic-specific keywords. Additional articles were found through structured email consultations with a large European expert network. Data availability was highly variable and important limitations existed in comparability and representativeness. Nine of 27 countries had data on HCV incidence among PWID, which was often high (2.7-66/100 person-years, median 13, Interquartile range (IQR) 8.7–28). Most common HCV genotypes were G1 and G3; however, G4 may be increasing, while the proportion of traditionally 'difficult to treat' genotypes (G1+G4) showed large variation (median 53, IQR 43–62). Twelve countries reported on HCV chronicity (median 72, IQR 64–81) and 22 on HIV prevalence in HCV-infected PWID (median 3.9%, IQR 0.2–28). Undiagnosed infection, assessed in five countries, was high (median 49%, IQR 38–64), while of those diagnosed, the proportion entering treatment was low (median 9.5%, IQR 3.5–15). Burden of disease, where assessed, was high and will rise in the next decade. Conclusion: Key data on HCV epidemiology, care and disease burden among PWID in Europe are sparse but suggest many undiagnosed infections and poor treatment uptake. Stronger efforts are needed to improve data availability to guide an increase in HCV treatment among PWID.
BASE